We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.75B
AUM Growth
-$879M
Cap. Flow
-$770M
Cap. Flow %
-44.05%
Top 10 Hldgs %
36.57%
Holding
112
New
6
Increased
25
Reduced
47
Closed
16

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$12.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$12M
3
EVH icon
Evolent Health
EVH
+$6.42M
4
MRUS
Merus
MRUS
+$3.85M
5
ACHC icon
Acadia Healthcare
ACHC
+$3.72M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$63M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$55.9M
3
FRPT icon
Freshpet
FRPT
+$48.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$41.7M
5
UNH icon
UnitedHealth
UNH
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Consumer Staples 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
76
Jasper Therapeutics
JSPR
$30.7M
$2.34M 0.13%
545,171
+82,083
+18% +$546K
LENZ
77
LENZ Therapeutics
LENZ
$163M
$2.14M 0.12%
83,082
+53,777
+184% +$1.32M
REGN icon
78
Regeneron Pharmaceuticals
REGN
$83B
$1.78M 0.1%
+2,800
New +$1.93M
APLS
79
DELISTED
Apellis Pharmaceuticals
APLS
$1.75M 0.1%
80,000
– –
BCRX icon
80
BioCryst Pharmaceuticals
BCRX
$2.65B
$1.67M 0.1%
222,011
-2,455,985
-92% -$19.8M
MGNX icon
81
MacroGenics
MGNX
$253M
$1.45M 0.08%
1,145,214
+91,567
+9% +$239K
CGEN icon
82
Compugen
CGEN
$227M
$1.45M 0.08%
989,990
– –
MRSN
83
DELISTED
Mersana Therapeutics
MRSN
$1.31M 0.08%
152,587
+15,320
+11% +$236K
NGNE icon
84
Neurogene
NGNE
$704M
$1.22M 0.07%
104,339
+8,932
+9% +$155K
AMLX icon
85
Amylyx Pharmaceuticals
AMLX
$2.63B
$1.22M 0.07%
+343,228
New +$1.22M
SION
86
Sionna Therapeutics
SION
$222M
$1.04M 0.06%
+99,429
New +$1.62M
APLT
87
DELISTED
Applied Therapeutics
APLT
$1.01M 0.06%
2,074,891
+157,700
+8% +$92.9K
CATX icon
88
Perspective Therapeutics
CATX
$358M
$947K 0.05%
444,383
– –
VIGL
89
DELISTED
Vigil Neuroscience
VIGL
$840K 0.05%
471,958
– –
PLRX icon
90
Pliant Therapeutics
PLRX
$65M
$796K 0.05%
589,996
+185,200
+46% +$1.12M
SPRB
91
Spruce Biosciences
SPRB
$127M
$757K 0.04%
34,788
– –
KRRO icon
92
Korro Bio
KRRO
$201M
$622K 0.04%
35,719
– –
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
$489K 0.03%
2,483,468
– –
TLPH icon
94
Talphera
TLPH
$75.8M
$157K 0.01%
316,460
– –
NUVB.WS
95
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$32K ﹤0.01%
134,028
– –
ABOS icon
96
Acumen Pharmaceuticals
ABOS
$181M
– –
-1,838,916
Closed -$3.16M
ALLK
97
DELISTED
Allakos
ALLK
– –
-1,100,409
Closed -$1.33M
AUTL
98
Autolus Therapeutics
AUTL
$639M
– –
-1,032,988
Closed -$2.43M
BHVN icon
99
Biohaven
BHVN
$2.12B
– –
-129,858
Closed -$4.85M
BMEA icon
100
Biomea Fusion
BMEA
$94.2M
– –
-181,147
Closed -$703K
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rock Springs Capital Management held 112 positions worth $1.75B, down 33% from $2.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $770M in Q1 2025, closing 16 positions and reducing 47 holdings. Its most notable exit was Freshpet, an estimated $48.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Danaher worth $12.1M.

  • Rock Springs Capital Management's largest Q1 2025 buy was Danaher: 58,800 shares worth $12.1M.
  • Rock Springs Capital Management added most to Tarsus Pharmaceuticals in Q1 2025, an estimated $12M increase.
  • Rock Springs Capital Management's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $63M.
  • Rock Springs Capital Management fully exited Freshpet in Q1 2025, selling an estimated $48.5M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $1.75B portfolio in Q1 2025.
  • Rock Springs Capital Management opened 6 new positions and closed 16 in Q1 2025.
  • Rock Springs Capital Management's portfolio value fell 33% quarter-over-quarter to $1.75B.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.